Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.77 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.65 |
| ▸ | PLD2 | O14939 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709114 | 0.93 | CYP2D6 (0.74) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL31000422 | 0.93 | CYP2D6 (0.74) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL24708725 | 0.92 | CHRM1 (0.73) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL6404540 | 0.90 | PLD1 (0.81) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL3665096 | 0.87 | OPRM1 (1.00) | OPRM1OPRK1OPRL1CHRM1DRD2 | |
| SCHEMBL5984495 | 0.87 | CYP2D6 (0.85) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL6487094 | 0.86 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL6404859 | 0.86 | CHRM1 (0.88) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL13959551 | 0.85 | OPRM1 (0.70) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 | |
| SCHEMBL3671916 | 0.85 | CHRM1 (0.72) | OPRM1OPRK1OPRL1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4353713-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Kinki University (JP) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | disclosed |
| EP-0898568-B1 | 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY | NEUROSEARCH AS (DK) | 2006-10-04 | — | — | EP | disclosed |
| US-6180649-B1 | NERVOUS SYSTEM DISORDERS; ALZHEIMER'S, HUNTINGTON, PARKINSON DISEASE | NEROSEARCH A/S (DK) | 2001-01-30 | — | — | US | disclosed |
| EP-0898568-A1 | 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040035-A1 | 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1G, CACNA1I, CACNA1H | OPRM1 877/4885OPRK1 739/4885OPRL1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.